Form 4 Filing for BioStem Technologies, Inc.

This filing details transactions by Jason Matuszewski, CEO of BioStem Technologies, Inc. On October 7, 2026, Matuszewski acquired 250,000 shares of common stock at $2.00 per share, increasing his post-transaction holdings to 1,553,551 shares. Additionally, he disposed of 250,000 options to buy common stock, with a strike price of $2.00, resulting in 2,000,000 options outstanding. The filing also corrects a previous overstatement of one share in restricted stock units due to an administrative error. Footnotes clarify the convertibility of Series A-1 Preferred Shares, vesting schedules for options and restricted stock units, and an omission of Series A-1 Preferred Shares in a prior filing.